INGENASA is a Biotech SME dedicated to research, development and marketing of products designed to the diagnosis and prevention of infectious diseases, especially those affecting the Animal Health sector. The facilities of INGENASA are located on two floors from adjoining buildings, with a total area of 2000 m2. All the activities performed in these facilities have the specific permission required. The company is ISO 9001 and ISO 14001 certified. The company based in Madrid has 49 employees, mostly women, and has more than 30 years’ experience in the production of recombinant proteins and monoclonal antibodies which  are used for the development of diagnostic test for many veterinary diseases, which are currently commercialized. The research activities (50% of the total sales) are partially funded by national grants from the Spanish Governmental Agencies and from European Union Framework Programmes. Based on this research INGENASA has registered more than  86 patents in 16 different families and 110  publications in peer-review journals. The company hosts different laboratories covering different areas (Molecular Biology, Immunology/Virology, Biochemistry, cell tissue culture, etc.). All of them have the proper equipment to carry out all the steps involved in the researching process. High-throughput equipment assisted by robotic technology is available for the rapid screening of multiple biological samples by ELISA. Moreover, Immunochromatographic technology is well established and protein microarray systems (planar microarrays and suspension microarrays) have been recently acquired and implemented in the company.

Web page: 

Key publications

  • Fleury A, Sastre P, Sciutto E, Correia S, Monedero A, Toledo A, Hernandez M, Harrison LJ, Parkhouse RM. A lateral flow assay (LFA) for the rapid detection of extraparenchymal neurocysticercosis using cerebrospinal fluid. Exp Parasitol. 2016 Oct 27. pii: S0014-4894(16)30277-6. doi: 10.1016/j.exppara.2016.10.016.
  • Sastre P, Gallardo C, Monedero A, Ruiz T, Arias M, Sanz A, Rueda P Development of a novel lateral flow assay for detection of African swine fever in blood. BMC Vet Res. 2016 Sep 15;12:206. doi: 10.1186/s12917-016-0831-4.
  • Costa S, Sastre P, Pérez T, Tapia I, Barrandeguy M, Sánchez-Vizcaíno JM, Sánchez-Matamoros A, Wigdorovitz A, Sanz A, Rueda P. Development and evaluation of a new lateral flow assay for simultaneous detection of antibodies against African Horse Sickness and Equine Infectious Anemia viruses. J Virol Methods. 2016 Nov;237:127-131. doi: 10.1016/j.jviromet.2016.09.009.
  • Sastre P. et al. Seroprevalence of human respiratory syncytial virus and human metapneumovirus in healthy population analyzed by recombinant fusion protein-based enzyme linked immunosorbent assay. Virol J., 9:130 (2012).
  • Sastre P. et al. Differentiation between human coronaviruses NL63 and 229E using a novel double-antibody sandwich enzyme-linked immunosorbent assay based on specific monoclonal antibodies. Clin. Vacc. Immunol., 18: 113–118J (2011).

Staff involved in HONOURs

Dr. Patricia Sastre

       P_Sastre zonder streep

Dr. Patricia Sastre has large expertise in viral protein expression in different systems and development of immunoassays (ELISA,  LFA and arrays) for virus and antibody detection. She will be involved in the supervision of ESR-10.

Dr. Paloma Rueda


Dr. Paloma is the Head of the Research Department in INGENASA and will be also involved in the supervision and training of the ESR-10.


Host switching pathogens, infectious outbreaks and zoonosis; a Marie Sklodowska-Curie Innovative Training Network.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 721367.